Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Benzinga

2021-08-19

Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients.
Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.
The results showed that the reflux (the backward flow of blood) decreased from 1.95 to an average of .72 (a 63% improvement).
Disease manifestations decreased from an average of 13.38 to an average of 5.38 (a 60% improvement).
Pain decreased from an average of 7.25 to an average of .50 (an improvement of 93%).
There were no safety issues or venous ulcer recurrences.
The VenoValve is a potential treatment for chronic Venous Insufficiency (CVI), a disease when valves inside the leg's veins fail, causing blood to flow in the wrong direction and creating increased pressure inside of the veins of the leg.
Related: FDA Breakthrough Designation For Its Venous Insufficiency Device.
Price Action: HJLI shares are down 4.29% at $7.14 during the market session on the last check Thursday.

See more from Benzinga

Click here for options trades from Benzinga
Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action
NLS Pharma Stock Gains After Issuance Of Mazindol Patent

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2160250793"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2160250793\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2160250793?lang=zh_CN&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/W1VU5NXoeOklS4J17UGuUA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Bih0obOqAiTJL3YNmgwYhg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a96896e1e63789936f17d5d0b6eed91d","is_english":true,"pubTime":"2021-08-19 23:49","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2160250793","market":"us","top_or_hot":-1,"title":"Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve","media":"Benzinga","content":"<html><body><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/VRSnnXWuZ5LiJ.XdtF0LPA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/a96896e1e63789936f17d5d0b6eed91d\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>Hancock Jaffe Laboratories Inc</strong> (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients.</li>\n<li>Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.</li>\n<li>The results showed that the reflux (the backward flow of blood) decreased from 1.95 to an average of .72 (a 63% improvement).</li>\n<li>Disease manifestations decreased from an average of 13.38 to an average of 5.38 (a 60% improvement).</li>\n<li>Pain decreased from an average of 7.25 to an average of .50 (an improvement of 93%).</li>\n<li>There were no safety issues or venous ulcer recurrences.</li>\n<li>The VenoValve is a potential treatment for chronic Venous Insufficiency (CVI), a disease when valves inside the leg's veins fail, causing blood to flow in the wrong direction and creating increased pressure inside of the veins of the leg.</li>\n<li><em>Related: </em><em>FDA Breakthrough Designation For Its Venous Insufficiency Device</em><em>.</em></li>\n<li><strong>Price Action:</strong> HJLI shares are down 4.29% at $7.14 during the market session on the last check Thursday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>Click here for options trades from Benzinga</li>\n<li>Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action</li>\n<li>NLS Pharma Stock Gains After Issuance Of Mazindol Patent</li>\n</ul>\n<p><i>© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-19 23:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/hancock-jaffe-highlights-two-data-154955177.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients.\nData will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/hancock-jaffe-highlights-two-data-154955177.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HBHC","symbol_name":"汉考克控股银行","start_time":0,"source_url":"https://finance.yahoo.com/news/hancock-jaffe-highlights-two-data-154955177.html","article_id":"2160250793","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/W1VU5NXoeOklS4J17UGuUA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Bih0obOqAiTJL3YNmgwYhg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a96896e1e63789936f17d5d0b6eed91d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2160250793","pubTimestamp":1629388195,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HBHC":"汉考克控股银行"},"translate_title":"汉考克·贾菲强调静脉功能不全瓣膜的两年数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HBHC":1,"HJLI":0.9},"content_text":"Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients.\nData will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.\nThe results showed that the reflux (the backward flow of blood) decreased from 1.95 to an average of .72 (a 63% improvement).\nDisease manifestations decreased from an average of 13.38 to an average of 5.38 (a 60% improvement).\nPain decreased from an average of 7.25 to an average of .50 (an improvement of 93%).\nThere were no safety issues or venous ulcer recurrences.\nThe VenoValve is a potential treatment for chronic Venous Insufficiency (CVI), a disease when valves inside the leg's veins fail, causing blood to flow in the wrong direction and creating increased pressure inside of the veins of the leg.\nRelated: FDA Breakthrough Designation For Its Venous Insufficiency Device.\nPrice Action: HJLI shares are down 4.29% at $7.14 during the market session on the last check Thursday.\n\nSee more from Benzinga\n\nClick here for options trades from Benzinga\nGalmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action\nNLS Pharma Stock Gains After Issuance Of Mazindol Patent\n\n© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}